Profitability
This table compares Pasithea Therapeutics and MusclePharm’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pasithea Therapeutics | N/A | -81.57% | -74.31% |
| MusclePharm | -38.51% | N/A | -169.56% |
Insider and Institutional Ownership
23.9% of Pasithea Therapeutics shares are held by institutional investors. Comparatively, 15.5% of MusclePharm shares are held by institutional investors. 16.3% of Pasithea Therapeutics shares are held by insiders. Comparatively, 60.7% of MusclePharm shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Pasithea Therapeutics and MusclePharm”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pasithea Therapeutics | $20,000.00 | 167.75 | -$15.96 million | N/A | N/A |
| MusclePharm | $50.04 million | 0.00 | -$12.87 million | ($0.58) | 0.00 |
Risk and Volatility
Pasithea Therapeutics has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, MusclePharm has a beta of -0.07, indicating that its share price is 107% less volatile than the S&P 500.
Summary
Pasithea Therapeutics beats MusclePharm on 5 of the 9 factors compared between the two stocks.
About Pasithea Therapeutics
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
About MusclePharm
MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada.
Receive News & Ratings for Pasithea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pasithea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
